Crizotinib treatment for refractory pediatric acute myeloid leukemia with RAN-binding protein 2-anaplastic lymphoma kinase fusion gene

Detalles Bibliográficos
Autores principales: Hayashi, A, Tanoshima, R, Tsujimoto, S-I, Yanagimachi, M, Takeuchi, M, Sasaki, K, Ikeda, J, Kajiwara, R, Ito, S, Takahashi, H
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2016
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5022176/
https://www.ncbi.nlm.nih.gov/pubmed/27494825
http://dx.doi.org/10.1038/bcj.2016.52
_version_ 1782453471465701376
author Hayashi, A
Tanoshima, R
Tsujimoto, S-I
Yanagimachi, M
Takeuchi, M
Sasaki, K
Ikeda, J
Kajiwara, R
Ito, S
Takahashi, H
author_facet Hayashi, A
Tanoshima, R
Tsujimoto, S-I
Yanagimachi, M
Takeuchi, M
Sasaki, K
Ikeda, J
Kajiwara, R
Ito, S
Takahashi, H
author_sort Hayashi, A
collection PubMed
description
format Online
Article
Text
id pubmed-5022176
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-50221762016-09-20 Crizotinib treatment for refractory pediatric acute myeloid leukemia with RAN-binding protein 2-anaplastic lymphoma kinase fusion gene Hayashi, A Tanoshima, R Tsujimoto, S-I Yanagimachi, M Takeuchi, M Sasaki, K Ikeda, J Kajiwara, R Ito, S Takahashi, H Blood Cancer J Letter to the Editor Nature Publishing Group 2016-08 2016-08-05 /pmc/articles/PMC5022176/ /pubmed/27494825 http://dx.doi.org/10.1038/bcj.2016.52 Text en Copyright © 2016 The Author(s) http://creativecommons.org/licenses/by/4.0/ This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/
spellingShingle Letter to the Editor
Hayashi, A
Tanoshima, R
Tsujimoto, S-I
Yanagimachi, M
Takeuchi, M
Sasaki, K
Ikeda, J
Kajiwara, R
Ito, S
Takahashi, H
Crizotinib treatment for refractory pediatric acute myeloid leukemia with RAN-binding protein 2-anaplastic lymphoma kinase fusion gene
title Crizotinib treatment for refractory pediatric acute myeloid leukemia with RAN-binding protein 2-anaplastic lymphoma kinase fusion gene
title_full Crizotinib treatment for refractory pediatric acute myeloid leukemia with RAN-binding protein 2-anaplastic lymphoma kinase fusion gene
title_fullStr Crizotinib treatment for refractory pediatric acute myeloid leukemia with RAN-binding protein 2-anaplastic lymphoma kinase fusion gene
title_full_unstemmed Crizotinib treatment for refractory pediatric acute myeloid leukemia with RAN-binding protein 2-anaplastic lymphoma kinase fusion gene
title_short Crizotinib treatment for refractory pediatric acute myeloid leukemia with RAN-binding protein 2-anaplastic lymphoma kinase fusion gene
title_sort crizotinib treatment for refractory pediatric acute myeloid leukemia with ran-binding protein 2-anaplastic lymphoma kinase fusion gene
topic Letter to the Editor
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5022176/
https://www.ncbi.nlm.nih.gov/pubmed/27494825
http://dx.doi.org/10.1038/bcj.2016.52
work_keys_str_mv AT hayashia crizotinibtreatmentforrefractorypediatricacutemyeloidleukemiawithranbindingprotein2anaplasticlymphomakinasefusiongene
AT tanoshimar crizotinibtreatmentforrefractorypediatricacutemyeloidleukemiawithranbindingprotein2anaplasticlymphomakinasefusiongene
AT tsujimotosi crizotinibtreatmentforrefractorypediatricacutemyeloidleukemiawithranbindingprotein2anaplasticlymphomakinasefusiongene
AT yanagimachim crizotinibtreatmentforrefractorypediatricacutemyeloidleukemiawithranbindingprotein2anaplasticlymphomakinasefusiongene
AT takeuchim crizotinibtreatmentforrefractorypediatricacutemyeloidleukemiawithranbindingprotein2anaplasticlymphomakinasefusiongene
AT sasakik crizotinibtreatmentforrefractorypediatricacutemyeloidleukemiawithranbindingprotein2anaplasticlymphomakinasefusiongene
AT ikedaj crizotinibtreatmentforrefractorypediatricacutemyeloidleukemiawithranbindingprotein2anaplasticlymphomakinasefusiongene
AT kajiwarar crizotinibtreatmentforrefractorypediatricacutemyeloidleukemiawithranbindingprotein2anaplasticlymphomakinasefusiongene
AT itos crizotinibtreatmentforrefractorypediatricacutemyeloidleukemiawithranbindingprotein2anaplasticlymphomakinasefusiongene
AT takahashih crizotinibtreatmentforrefractorypediatricacutemyeloidleukemiawithranbindingprotein2anaplasticlymphomakinasefusiongene

Ejemplares similares